Kristin Anne Connarn

Kristin A. Connarn leverages her background in biotechnology and cancer research to effectively guide clients through strategic patent portfolio development and management. Her practice focuses on life sciences patent prosecution, portfolio development, and management in the biotechnology and pharmaceutical sectors.

Kristin's clients range from startups to international pharmaceutical companies, nonprofits, medical centers, and universities, as well as venture capital and private equity investors. She supports clients in strategic counseling, patent portfolio development and management, and patent prosecution. She also guides clients through transactions and agreements that involve intellectual property assets, including joint development agreements, sponsored research agreements, licenses, and complex commercial transactions.

Kristin has vast experience working with companies developing novel biologics in the cell and gene therapy spaces, including oncology, autoimmune, and inflammatory diseases. She assists clients in developing and executing IP protection strategies on therapeutic antibodies, recombinant proteins, targeted delivery of therapeutic including using antibodies and nanoparticles, and therapies including microbiome transplantations, CAR-T, CAR-NK, and TCR-T cells. Kristin also works with companies developing biologics to treat and prevent infections, including COVID-19.

Kristin's patent prosecution experience includes methods of treatment and diagnostics, dry powder inhalation therapies, food science, vaccines, and medical devices. She develops and delivers trainings for in-house legal and scientific teams regarding invention disclosures, patentability, and inventorship.

Kristin has industry experience as a researcher for the Cancer Bioscience and CNS groups at AstraZeneca R&D Boston, where she applied molecular and cell biology techniques to research cancer and Alzheimer's disease. She also researched gene activation with Transkaryotic Therapies.